You are here

Valeant's new chief cuts a familiar figure

Joseph Papa pursued a series of strategies at Perrigo that were similar to the drugmaker's discredited business model

drug030516.jpg
When a deeply troubled company replaces its chief executive, it makes sense to expect the new CEO to bring a fresh take to its operations.

New York

WHEN a deeply troubled company replaces its chief executive, it makes sense to expect the new CEO to bring a fresh take to its operations. A clean sweep, so to speak.

But if shareholders in Valeant Pharmaceuticals International envisage a vastly different approach by